Myriad Genetics MYGN Mental Health — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Myriad Genetics's mental health — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Myriad Genetics's mental health — revenue?
- Myriad Genetics (MYGN) reported mental health — revenue of $38.3M in Q1 2026.
- How has Myriad Genetics's mental health — revenue changed year-over-year?
- Myriad Genetics's mental health — revenue increased by 23.5% year-over-year, from $31M to $38.3M.
- What does mental health — revenue mean?
- This metric represents the total gross revenue generated from the sale of diagnostic testing services and products specifically focused on mental health and psychotropic drug response optimization. It reflects the commercial performance and market adoption of the company's psychiatric diagnostic portfolio. Monitoring this revenue stream provides insight into the company's diversification strategy and its ability to capture value within the behavioral health diagnostics market.